Research Article

Scolopendra subspinipes mutilans L. Koch Ameliorates Rheumatic Heart Disease by Affecting Relative Percentages of CD4$^+$ CD25$^+$ FoxP3 Treg and CD4$^+$ IL17 T Cells

Tiechao Jiang,1,2 Qini Zhao,1,2 Hongyan Sun,3 Lirong Zhang,3 Shanshan Song,4 Hongli Chi,5 and Hui Zhou6

1Department of Cardiovascular Medicine, China-Japan Union Hospital of Jilin University, Changchun 130033, China
2Jilin Provincial Precision Medicine Key Laboratory for Cardiovascular Genetic Diagnosis, Changchun 130033, China
3Department of Pathology, China-Japan Union Hospital of Jilin University, Changchun 130033, China
4Department of Radiology, College of Public Health, Jilin University, Changchun 130021, China
5Department of EICU, The First Hospital of Jilin University, Changchun 130021, China
6Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China

Correspondence should be addressed to Hongli Chi; chihl@jlu.edu.cn and Hui Zhou; zhohuijlu@126.com

Received 9 April 2019; Accepted 28 May 2019; Published 14 July 2019

Guest Editor: Gunhyuk Park

Copyright © 2019 Tiechao Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Scolopendra subspinipes mutilans L. Koch. (SSLK) helps reduce the risk of coronary heart disease (CHD) but its effects on rheumatic heart disease (RHD) patients remain unclear. 80 RHD patients were recruited and randomly assigned into SG (to receive SSLK treatment) and CG (to receive placebo) groups, and the intervention lasted for 3 months. The following cardiac indexes were measured, including mean arterial pressure (MAP), heart rate (HR), central venous pressure (CVP), blood lactate, fatigue, shortness of breath, palpitation, and chest pain. ELISA kits were used to analyze creatine kinase isoenzyme (CK-MB), serum troponin T (cTnT), CRP, IL-1β, IL-6, and TNF-α, malondialdehyde (MDA), and superoxide dismutase (SOD). Relative percentages of CD4$^+$ CD25$^+$ FoxP3 regulatory (Treg) and CD4$^+$ IL-17 T cells were measured using flow cytometry. After 3-month therapy, SSLK intervention improved MAP, HR, CVP, fatigue, palpitation, and shortness of breath of CHD patients, reduced the levels of blood lactate, CK-MB, cTnT, CRP, IL-1β, IL-6, TNF-α, MDA, and increased SOD level ($p < 0.05$). Meanwhile, SSLK treatment increased the percentages of CD4$^+$ CD25$^+$ FoxP3 Treg cells and reduced relative percentages of CD4$^+$ IL-17 T cells in a dose-dependent way ($p < 0.05$). Relative percentage of CD4$^+$ CD25$^+$ FoxP3 Treg cells had negative relationship while CD4$^+$ IL17 T cells had positive relationship with CK-MB, cTnT, CRP, and TNF-a ($p < 0.01$). SSLK ameliorated RHD by affecting the balance of CD4$^+$ CD25$^+$ FoxP3 Treg and CD4$^+$ IL17 T cells.

1. Introduction

Rheumatic heart disease (RHD) is a sequel of acute rheumatic fever (ARF) [1, 2] and an autoimmune disease caused by the damage to heart valves [3] or hemolytic streptococcal infection [4]. According to statistics, there are more than 15.6 million RHD patients in the world [5]. The prevention and treatment of RHD is still a common public health issue and causes a global burden. Antibiotics are often used in the treatment of RHD to prevent infection and the inflammation of the heart and other symptoms [6, 7]. However, a frequent and distressing complication often occurs after the treatment. Some pathogen can develop antibiotic resistance and make the treatment ineffective [8]. Furthermore, antibiotics produce toxicity [9] and cause drug-drug interaction [10], which will further contribute to RHD progression. It is highly needed to explore new effective medicine with fewer side effects.

Scolopendra subspinipes mutilans L. Koch (SSLK), ancient antipyretic traditional Chinese medicine, can improve blood circulation, relieve blood stasis [11], and prevent heart failure by attenuating postinfarct remodeling [12]. SSLK has been
reported to control vascular disease via its anti-inflammatory activities [13]. SSLK can reduce the risk of heart disease by improving the biochemical indices of patients [14]. More work indicates that SSLK can regulate fatty acids metabolism by exerting anti-adipogenic activity via the inhibition of the expression of C/EBPβ, C/EBPα, and PPARγ and the Akt signaling pathway in adipocytes [15].

It has been reported that CD4+ T cells are the major effector cells in the heart valve of RHD patients, and the number of these cells is increased in the peripheral blood of RHD patients [16]. There are approximately 5% to 10% of CD4+ T cells in peripheral blood and spleen tissues of healthy persons. CD25, TGF-beta, and forkhead box protein P3 (FoxP3) are highly expressed in T cells [17]. These proteins play crucial roles in the immunosuppressive functions of regulatory T (Treg) cells [18]. CD4+CD25+ Treg cells are generated in the thymus and have been reported to mitigate autoimmune myocarditis [19]. The dysfunction of CD4+CD25+ Treg cells may lead to RHD occurrence and FoxP3 regulates Treg cell development and function [20, 21]. CD4+IL-17 T cells have been reported to be associated with bacterial infection and inflammatory responses [22, 23].

SSLK reduces the risk of coronary heart disease (CHD) [24]. However, the effects of SSLK on RHD remain unknown and related molecular mechanisms are unclear. High-level Th17/Treg ratio has been found to be associated with the risk and progression of RHD [25]. CD4+IL17 T cells are the main Th17 cell subsets [26] and CD4+CD25+ FoxP3 Treg cells are the main Treg cell subsets [27]. Thus, SSLK may exert beneficial effects on RHD patients by affecting the levels of CD4+CD25+FoxP3 Treg and CD4+IL17 T cells. Therefore, in this study, peripheral blood samples were collected from RHD patients to investigate the effects of SSLK on regulatory T lymphocytes. To investigate the changes of relative percentages of CD4+CD25+ Treg and CD4+IL-17 T cells induced by SSLK, the study may provide new molecular mechanism for RHD treatment.

2. Materials and Methods
2.1. Materials. FITC mouse anti-human CD4 (Clone RPA-T4), an isotype control mouse IgG1-FITC (Clone MOPC-21), APC mouse anti-human CD25 (Clone M-A251), an isotype control anti-APC mouse IgG1 (Clone MOPC-21), PE Mouse anti-Human FoxP3 (Clone 259D/C7), and an isotype control PE mouse IgG1 (Clone MOPC-21) were purchased from BD Bioscience (BD Bioscience, San Jose, CA, USA). Ficoll-Paque was purchased from Sigma (Louis, MO, USA). M-MLV First Strand Kit was purchased from Invitrogen (Shanghai, China). Power SYBR Green PCR Master Mix was purchased from ABI (Foster, CA, USA).

2.2. Participants. The study was approved by the Human Research Ethics Committee of China-Japan Union Hospital of Jilin University (Changchun, China, approval no. 2015NXXY) and all participants signed informed consent. From November 2015 to July 2016, 227 CHD patients were recruited at our hospital. All patients were diagnosed with RHD based on clinical symptoms, rheumatic fever history, and cardiac ultrasonography.

2.3. Inclusion Criteria. All patients were diagnosed with rheumatic mitral valve disease by medical history, physical examination, laboratory examination, echocardiography, and surgery.

2.4. Exclusion Criteria. The patients would be excluded if they had the following symptoms: acute myocardial infarction and severe heart failure; psychiatric abnormalities and being unable to correctly describe their symptoms and other autoimmune system diseases (such as rheumatoid arthritis); or systemic lupus erythematosus.

2.5. Patient Grouping. After applying inclusion criteria and exclusion criteria, a total of 80 RHD patients entered the present study at China-Japan Union Hospital of Jilin University. SSLKs were purchased from Beijing Tongrentang Pharmacy (Beijing, Chin) to make fine powder. The patients were evenly and randomly assigned into two groups: SSLK (SG, orally given 100-mg SSLK powder every morning) and control (CG, orally given 100-mg placebo every morning). The whole duration of the treatment was three months. Liver function was measured using liver function monitoring system (LiMON Leberfunktionsmonitor, Pulsion Medical Systems AG, Munich, Germany). Renal function was measured using blood urea nitrogen, serum creatinine, and estimated glomerular filtration rate according to previous reports [28]. Meanwhile, side effects (dry mouth, diarrhea, dizziness, weakness, no appetite or nausea, headache, fatigue, nightmares, and so on) were measured according to self-reported physical activity.

2.6. Hemodynamics and Arterial Blood Gas Index. Dopamine would be considered when the severe condition of RHD occurred. Mean arterial pressure (MAP), heart rate (HR), central venous pressure (CVP, evaluated by ultrasound of the internal jugular vein), partial pressure of oxygen (PaO₂), and blood lactate levels were measured at 0 months, 1 month, 2 months, and 3 months.

2.7. Serum Levels of Inflammatory Cytokines. The serum concentrations of C-reactive protein (CRP, Cat. No. ab36176), tumor necrosis factor-a (TNF-a, Cat. No. ab9348), IL-1β (Cat. No. ab46052), IL-6 (Cat. No. ab178013), IL-10 (Cat. No. ab46034), and TGF-β (Cat. No. ab100647) were measured using the ELISA kits from Abcam (Shanghai, China).

2.8. Cardiac Biomarker Levels. After 0-, 1-, 2- and 3-month treatment, the creatine kinase isoenzyme (CK-MB), serum cardiac troponin T (cTnT), malondialdehyde (MDA), and superoxide dismutase (SOD) were detected by an automatic biochemical analyzer (Hitachi 7600P, Hitachi, Japan).

2.9. The Measurement of CD4+CD25+FoxP3 Treg and CD4+IL-17 T Cells. Five-mL venous blood was taken aseptically from each subject at 0 months and 3 months.
Evidence-Based Complementary and Alternative Medicine

### Table 1: Clinical characteristics of all participants.

|                         | SSLK group (N=40) | Control group (N=40) | t/χ² values | P values |
|-------------------------|-------------------|----------------------|-------------|----------|
| Age, (years)            | 47.85 ± 9.95      | 45.20 ± 9.99         | 0.984       | 0.324    |
| Female, n (%)           | 31(77.5)          | 28(70)               | 0.581       | 0.446    |
| BMI, kg/m²              | 23.92 ± 2.26      | 23.32 ± 2.47         | 0.157       | 0.873    |
| Smoking, n (%)          | 8 (20)            | 4 (10)               | 1.569       | 0.210    |
| Diabetes, n (%)         | 5 (12.5)          | 6 (15)               | 0.105       | 0.745    |
| Hypertension, n (%)     | 32(78)            | 33(82.5)             | 0.082       | 0.775    |
| Ongoing treatment       |                   |                      |             |          |
| Digoxin, n (%)          | 10(25)            | 8(20)                | 0.287       | 0.592    |
| Aspirin, n (%)          | 22(55)            | 23(57.5)             | 0.051       | 0.822    |
| NYHA classification     |                   |                      |             |          |
| II, n (%)               | 34(85)            | 35(87.5)             | 0.626       | 0.731    |
| III, n (%)              | 6(15)             | 8(20)                |             |          |
| AF, n (%)               | 38(95)            | 33(82.5)             |             |          |
| Mitral stenosis,        |                   |                      |             |          |
| Moderate, n (%)         | 20(50)            | 23(57.5)             | 0.188       | 0.664    |
| Severe, n (%)           | 15(37.5)          | 14(35)               |             |          |
| Aortic stenosis,        |                   |                      |             |          |
| Moderate, n (%)         | 3(7.5)            | 4(10)                |             |          |
| Severe, n (%)           | 2(5)              | 3(7.5)               |             |          |
| Tricuspid incompetence  |                   |                      |             |          |
| Mild, n (%)             | 28(70)            | 29(72.5)             | 0.583       | 0.747    |
| Moderate, n (%)         | 6(15)             | 8(20)                |             |          |
| Severe, n (%)           | 2(5)              | 1(2.5)               |             |          |
| Plasma measurements,    |                   |                      |             |          |
| Triglycerides,          | 2.16 ± 1.24       | 1.94 ± 1.77          | 0.763       | 0.482    |
| Total cholesterol (mmol/L), | 5.33 ± 1.36       | 4.67 ± 1.41          | 1.639       | 0.163    |
| LDL-C (mmol/L),         | 3.31 ± 0.89       | 3.46 ± 0.99          | 0.652       | 0.561    |
| HDL-C (mmol/L),         | 1.59 ± 0.67       | 1.68 ± 0.39          | 0.758       | 0.478    |

Note: SSLK, Scolopendra subspinipes mutilans L. Koch. BMI, body mass index. NYHA, the New York Heart Association; AF, atrial fibrillation; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

and heparinized anticoagulated. The blood samples were processed within 2 h. Five-mL venous blood and equal volume of sterile saline were used to dilute the venous blood and mixed thoroughly to extract peripheral blood mononuclear cells (PBMCs). PBMCs were prepared using Ficoll-Paque density gradient centrifugation. CD4⁺ cells were gated on forward and side scatter for lymphocyte purity in the gate. Relative percentages of CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T cells were analyzed by flow cytometry.

2.10. The Effects of SSLK on Relative Percentages of CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T Cells. Above PBMCs were cultured in DMEM medium with fetal bovine serum (Cat. No. TM999) to a final concentration of 10% and penicillin/streptomycin at 1%. The cells were adjusted to a density of 1 × 10⁵ cells/mL, added to a 96-cell plate (100 µL/per cell), and cultured at 95% air, 5% CO₂, and 37°C. SSLK powder was added to the medium with final concentration from 0 to 10 µg/mL. After 48 h, PBMCs were stained by surface marker CD4 and CD25 antibodies firstly. After fixation and permeabilization, PBMCs were then stained by Foxp3 and IL-17 antibodies. Relative percentages of CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T cells were analyzed by flow cytometry.

2.11. Statistical Analysis. SPSS18.0 statistical software was used for data analysis. Quantitative variables were expressed as mean values ± S.D. (standard derivative). Independent samples T-test and one-way analysis of variance (ANOVA) were used to compare the data difference between CG and SG groups. Chi-square test was used to compare the number difference between two groups. The correlation between two variables was analyzed using Pearson correlation coefficient test. p < 0.05 indicates the difference was statistically significant.

### 3. Results

3.1. Clinical Characteristics. The baseline clinical characteristics of RHD patients from two groups were shown in Table I. There was no significant difference in age, body mass
Table 2: The complications of rheumatic heart disease (RHD) patients between two groups.

| Parameters      | CG   | SG   | p values |
|-----------------|------|------|----------|
| 0 months        |      |      |          |
| Fatigue, cases  | 35   | 33   | 0.531    |
| Palpitation, cases | 30   | 31   | 0.793    |
| Dyspnea, cases  | 29   | 27   | 0.626    |
| Chest pain grades | 5   | 4    |          |
| 0               | 0    | 0    |          |
| 1               | 4    | 3    |          |
| 2               | 5    | 7    |          |
| 3               | 9    | 8    |          |
| 4               | 8    | 7    |          |
| 5               | 6    | 4    | 1.000    |
| 6               | 5    | 6    |          |
| 7               | 2    | 3    |          |
| 8               | 1    | 2    |          |
| 9               | 0    | 0    |          |
| 10              | 10   | 10   |          |
| 3 months        |      |      |          |
| Fatigue, cases  | 36   | 19   | 0.001    |
| Palpitation, cases | 30   | 21   | 0.036    |
| Dyspnea, cases  | 28   | 16   | 0.007    |
| Chest pain grades | 5   | 3    |          |
| 0               | 3    | 8    |          |
| 1               | 6    | 10   |          |
| 2               | 9    | 7    |          |
| 3               | 8    | 5    |          |
| 4               | 6    | 2    |          |
| 5               | 5    | 3    | 0.935    |
| 6               | 1    | 3    |          |
| 7               | 2    | 1    |          |
| 8               | 0    | 0    |          |
| 9               | 0    | 0    |          |
| 10              | 0    | 0    |          |

Note: The pain grade scores (0-10) were analyzed and higher pain grades were associated with more serious pain. The significant difference was analyzed by using a Chi-square test or one-way ANOVA. SG, SSLK group and CG, control group. There was significant difference if p < 0.05 vs. a control group.

3.3. SSLK Treatment Reduced the Level of Blood Lactate. The statistical differences for the levels of MAP, HR, CVP, arterial PaO2, and blood lactate content were insignificant between two groups at 0 months and 1 month (Table 3, p > 0.05); MAP, HR, CVP, PaO2, and blood lactate content in the SG were lower than in the CG group after 2 months (Table 3, p < 0.05). The results suggested that SSLK treatment could not affect MAP, HR, CVP, PaO2, and blood lactate in a short term.

3.4. SSLK Treatment Reduced the Inflammatory Cytokines Levels. The statistical differences for the levels of CRP, TNF-α, IL-1β, and IL-6 were insignificant between the two groups at 0 months (Table 4, p > 0.05). The concentrations of CRP, TNF-α, IL-1β, and IL-6 in the SG group were lower than in the CG group (Table 4, p < 0.05). The results suggested that SSLK reduced the inflammatory cytokines levels.

3.5. SSLK Treatment Improved Myocardial Enzyme Levels. The statistical differences of CK-MB, cTnT, MDA, and SOD levels were insignificant between the two groups (P < 0.05, Table 3). The concentrations of CK-MB, cTnT, and MDA in the SG group were lower than in the CG group while SOD had reverse results (Table 5, p < 0.05). The results suggested that SSLK treatment improved myocardial enzyme levels.

3.6. SSLK Treatment Improved Serum Levels of Inflammatory Factors. ELISA analysis showed that SSLK treatment reduced the serum levels of IL-1β (Figure 1(a)) and IL-6 (Figure 1(b)) and increased the levels of IL-10 (Figure 1(c)) and TGF-β (Figure 1(d)) when compared with the CG group (p < 0.05). SSLK treatment improved serum levels of inflammatory factors.

3.7. SSLK Treatment Affected Relative Percentages of CD4 CD25 FoxP3 Treg and CD4 IL-17 T Cells in PBMCs. Before SSLK intervention, the average percentages of CD4 CD25 FoxP3 Treg cells (Figure 2(a)) and CD4 IL-17 T cells (Figure 2(b)) were 3.5% and 7.2% in CG group, respectively. The average percentages of CD4 CD25 FoxP3 Treg cells (Figure 2(c)) and CD4 IL-17 T cells (Figure 2(d)) were 3.7% and 6.9%. The statistical differences for the percentages of CD4 CD25 FoxP3 Treg cells and CD4 IL-17 T cells were insignificant (p > 0.05). After 3-month SSLK intervention, the average percentages of CD4 CD25 FoxP3 Treg cells (Figure 2(e)) and CD4 IL-17 T cells (Figure 2(f)) were 3.2% and 6.5% in CG group, respectively. The average percentages of CD4 CD25 FoxP3 Treg cells (Figure 2(g)) and CD4 IL-17 T cells (Figure 2(h)) were 5.8% and 3.4% in the SG group, respectively. SSLK treatment increased the percentages of CD4 CD25 FoxP3 Treg cells (from 3.2 ± 0.5 to 5.8 ± 0.7) and reduced the percentages of CD4 IL-17 T cells (from 6.5 ± 0.9 to 3.4 ± 0.6). The results suggested that SSLK consumption affected the percentages of CD4 CD25 FoxP3 Treg cells and CD4 IL-17 T cells in PBMCs.

3.8. The Effects of SSLK on the Percentage of CD4 CD25 FoxP3 Treg and CD4 IL-17 T Cells in PBMCs. Figure 3 showed that SSLK increased the percentage of CD4 CD25 FoxP3 Treg...
Table 3: Comparison of hemodynamic parameters and arterial blood gas between two groups.

| Parameters          | 0 months     | 1 month     | 2 months    | 3 months    |
|---------------------|--------------|-------------|-------------|-------------|
| MAP/mmHg            |              |             |             |             |
| CG                  | 73.65 ± 4.16 | 77.49 ± 6.23| 78.21 ± 6.48| 78.92 ± 7.25|
| SG                  | 75.12 ± 3.85 | 73.20 ± 5.76| 70.33 ± 7.16| 70.93 ± 7.64|
| F                   | 0.245        | 0.268       | 2.495       | 2.996       |
| p values            | 0.687        | 0.612       | 0.035       | 0.027       |
| HR (times/min)      |              |             |             |             |
| CG                  | 76.48 ± 13.54| 81.26 ± 15.37| 80.38 ± 15.89| 81.32 ± 15.71|
| SG                  | 77.62 ± 12.36| 76.34 ± 9.18 | 70.96 ± 12.53| 70.13 ± 13.99|
| F                   | 0.109        | 0.436       | 3.168       | 3.656       |
| p values            | 0.853        | 0.375       | 0.039       | 0.024       |
| CVP/cmH2O           |              |             |             |             |
| CG                  | 15.41 ± 2.12 | 13.42 ± 3.84 | 14.61 ± 4.23 | 14.58 ± 4.35 |
| SG                  | 15.65 ± 2.05 | 11.95 ± 4.13 | 10.36 ± 4.38 | 9.87 ± 4.69  |
| F                   | 0.063        | 1.169       | 4.219       | 5.324       |
| p values            | 0.869        | 0.082       | 0.012       | 0.003       |
| PaO2/mmHg           |              |             |             |             |
| CG                  | 156.26 ± 62.35| 138.52 ± 40.24| 130.44 ± 42.19| 134.48 ± 43.01|
| SG                  | 168.23 ± 59.35| 130.78 ± 35.17| 111.36 ± 40.14| 114.53 ± 42.38|
| F                   | 0.246        | 0.835       | 3.237       | 3.064       |
| p values            | 0.627        | 0.102       | 0.027       | 0.031       |
| Blood lactate/mmol/L|              |             |             |             |
| CG                  | 0.47 ± 0.10  | 0.85 ± 0.26  | 1.36 ± 0.36  | 1.34 ± 0.21  |
| SG                  | 0.51 ± 0.16  | 0.73 ± 0.39  | 1.21 ± 0.30  | 1.22 ± 0.33  |
| F                   | 0.878        | 1.943       | 2.053       | 2.246       |
| p values            | 0.126        | 0.051       | 0.042       | 0.039       |

Note: MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure; PaO2, Partial Pressure of Oxygen. SG, SSLK group and CG, control group. There was significant difference if p < 0.05 vs. a control group.

Table 4: The concentrations of CRP, TNF-α, IL-1, and IL-6 between two groups.

| Parameters          | 0 months     | 1 month     | 2 months    | 3 months    |
|---------------------|--------------|-------------|-------------|-------------|
| CRP (µg/mL)         |              |             |             |             |
| CG                  | 9.81 ± 1.32  | 79.36 ± 8.57| 76.15 ± 9.25| 56.23 ± 5.26|
| SG                  | 10.12 ± 1.26 | 62.21 ± 6.29| 45.62 ± 3.26| 39.58 ± 3.54|
| F                   | 0.563        | 2.140       | 14.363      | 12.072      |
| p values            | 0.451        | 0.022       | 0.001       | 0.001       |
| TNF-α (pg/mL)       |              |             |             |             |
| CG                  | 11.32 ± 3.24 | 45.31 ± 5.26| 24.15 ± 5.05| 22.23 ± 4.25|
| SG                  | 10.29 ± 3.18 | 34.18 ± 2.95| 18.23 ± 3.12| 12.68 ± 2.52|
| F                   | 1.027        | 9.741       | 13.981      | 15.327      |
| p values            | 0.068        | 0.003       | 0.002       | 0.001       |
| IL-6/(ng/L)         |              |             |             |             |
| CG                  | 21.15 ± 3.26 | 53.62 ± 11.05| 68.29 ± 10.26| 35.21 ± 9.26|
| SG                  | 20.59 ± 3.52 | 34.26 ± 5.62 | 23.46 ± 3.52 | 17.62 ± 4.76|
| F                   | 0.217        | 12.451      | 22.461      | 38.972      |
| p values            | 0.082        | 0.001       | 0.001       | 0.001       |
| IL-1/(ng/L)         |              |             |             |             |
| CG                  | 18.26 ± 4.26 | 67.59 ± 8.26 | 59.26 ± 7.52 | 43.26 ± 5.21|
| SG                  | 18.15 ± 4.31 | 53.26 ± 6.05 | 31.25 ± 6.20 | 21.36 ± 4.74|
| F                   | 0.116        | 8.642       | 12.673      | 36.519      |
| p values            | 0.824        | 0.003       | 0.001       | 0.001       |

Note: CRP, C-creative protein; TNF-α, tumor necrosis factor; IL-1, interleukin-1; IL-6, interleukin-6. SG, SSLK group and CG, control group. There was significant difference if p < 0.05 vs. a control group.

3.9. The Percentage of CD4⁺CD25⁺FoxP3 Treg Cells Had Negative Relationship with CK-MB, cTnT, CRP, and TNF-α. Pearson correlation coefficient test showed that, with the increase in the percentage of CD4⁺CD25⁺FoxP3 Treg cells, the levels of CK-MB (Figure 4(a)), cTnI (Figure 4(b)), CRP cells (Figure 3(a)) and reduced the percentage of CD4⁺IL-17 T cells (Figure 3(b)) in a dose-dependent way in PBMCs. The results showed that SSLK intervention regulated the percentages of CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T cells in PBMCs.
Table 5: Comparison of cardiac marker between two groups.

| Parameters | 0 months | 1 month | 2 months | 3 months |
|------------|----------|---------|----------|----------|
| CK-MB/CG (ng/mL) | 7.61 ± 1.52 | 41.35 ± 12.20 | 52.26 ± 13.36 | 33.65 ± 8.26 |
| SG | 7.26 ± 1.46 | 26.58 ± 10.54 | 34.69 ± 11.25 | 21.26 ± 7.26 |
| F p values | 0.098 | 32.147 | 22.654 | 18.761 |
| 0.912 | 0.001 | 0.001 | 0.001 |
| cTnI/(ng/mL) CG | 0.01 ± 0.01 | 0.61 ± 0.23 | 1.38 ± 0.51 | 0.84 ± 0.35 |
| SG | 0.01 ± 0.01 | 0.41 ± 0.28 | 0.76 ± 0.21 | 0.28 ± 0.12 |
| F p values | 0 | 16.423 | 25.349 | 45.678 |
| 1.000 | 0.002 | 0.001 | 0.001 |
| MDA/CG (nmol/mL) | 3.51 ± 0.89 | 7.68 ± 0.65 | 7.34 ± 0.58 | 6.84 ± 0.48 |
| SG | 3.48 ± 0.79 | 5.87 ± 0.79 | 5.74 ± 0.83 | 4.26 ± 0.36 |
| F p values | 0.082 | 9.856 | 10.154 | 15.483 |
| 0.947 | 0.002 | 0.001 | 0.001 |
| SOD/CG (UN/mL) | 120.35 ± 18.26 | 66.82 ± 17.65 | 78.52 ± 23.15 | 84.51 ± 26.03 |
| SG | 119.45 ± 17.36 | 88.26 ± 13.62 | 95.62 ± 24.58 | 108.26 ± 25.15 |
| F p values | 0.085 | 14.872 | 16.485 | 20.163 |
| 0.793 | 0.002 | 0.001 | 0.001 |

Note: CK-MB, creatine kinase isoenzyme; cTnI, cardiac troponin T; MDA, malondialdehyde and SOD, superoxide dismutase. SG, SSLK group and CG, control group. There was significant difference if $p < 0.05$ vs a control group.

Figure 1: ELISA analysis of the effects of SSLK on the levels of cytokines and transcription factor. (a), the effects of SSLK on serum levels of IL-1β. (b), the effects of SSLK on serum levels of IL-6. (c), the effects of SSLK on serum levels of IL-10. (d), the effects of SSLK on the levels of TGF-β. In the SG group, the patients took SSLK and in the CG group, the patients took placebo (n = 40 for each group). *$p < 0.05$ via a control group.
Figure 2: Flow cytometry analysis of the percentage of CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T cells in PBMCs. (a), the percentage of CD4⁺CD25⁺FoxP3 Treg cells in the CG group before placebo intervention. (b), the percentage of CD4⁺IL-17 T cells in the CG group before placebo intervention. (c), the percentage of CD4⁺CD25⁺FoxP3 Treg cells in the SG group before SSLK intervention. (d), the percentage of CD4⁺IL-17 T cells in the SG group before SSLK intervention. (e), the percentage of CD4⁺CD25⁺FoxP3 Treg cells in the CG group after 3-month placebo intervention. (f), the percentage of CD4⁺IL-17 T cells in the CG group after 3-month placebo intervention. (g), the percentage of CD4⁺CD25⁺FoxP3 Treg cells in the SG group after 3-month SSLK intervention. (h), the percentage of CD4⁺IL-17 T cells in the SG group after 3-month SSLK intervention. In the SG group, the patients took SSLK and in the CG group, the patients took placebo.
Figure 3: The effects of SSLK on the percentage of CD4+CD25+FoxP3 Tregs and CD4+IL-17 T cells in PBMCs. (a), The effects of SSLK on the percentage of CD4+IL-17 T cells in PBMCs. (b), the effects of SSLK on the percentage of CD4+CD25+FoxP3 Treg cells in PBMCs. *p < 0.05 and **p < 0.01 via the 0-μg/ml group.

Figure 4: The relationship between the percentage of CD4+CD25+FoxP3 Tregs and CK-MB, cTnT, CRP and TNF-α. (a), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and CK-MB. (b), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and cTnT. (c), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and CRP. (d), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and TNF-α. There was a strong negative relationship between two variables if rho values < -0.5.

(Figure 4(c)), and TNF-α (Figure 4(d)) were reduced. The percentage of CD4+CD25+FoxP3 Treg cells had negative relationship with the levels of CK-MB, cTnT, CRP, and TNF-α since rho < -0.5 and p < 0.01.

3.10. The Percentage of CD4+ IL-17 T Cells Had Positive Relationship with CK-MB, cTnT, CRP, and TNF-α. Pearson correlation coefficient test showed that, with the increase in the percentage of CD4+ IL-17 T cells, the levels of CK-MB...
Figure 5: The relationship between the percentage of CD4^+ IL-17 T cells and CK-MB, cTnI, CRP, and TNF-α. (a), the relationship between the percentage of CD4^+ IL-17 T cells and CK-MB. (b), the relationship between the percentage of CD4^+ IL-17 T cells and cTnI. (c), the relationship between the percentage of CD4^+ IL-17 T cells and CRP. (d), the relationship between the percentage of CD4^+ IL-17 T cells and TNF-α. There was a strong negative relationship between two variables if rho values > 0.5.

4. Discussion

SSLK reduced the levels of cardiac biomarkers (CK-MB and cTnI) and inflammatory cytokines in RHD patients (Table 4 and Figure 1), suggesting it can regulate inflammatory activity of patients. The reduction of CD4^+ CD25^+ FoxP3 Treg cells and the increase in CD4^+ IL-17 cells in PBMCs may be associated with poor prognosis of RHD. CD4^+ CD25^-Tregs [29] and CD4^+ CD25^+ FoxP3 Treg cells [30] regulated the immune activity in heart disease. Relative percentages of CD4^+ CD25^- Tregs and CD4^+ CD25^+ FoxP3 Treg cells in PBMCs in the SG group were higher than in the CG group (Figure 2, P<0.05). SSLK has antibacterial [31], anticoagulant [32], and anti-inflammatory [33] properties. SSLK intervention may improve CHD symptoms of the patients by increasing the percentage of CD4^+ CD25^+ FoxP3 Treg cells and reducing the percentage of CD4^+ IL-17 cells in PBMCs and maintained their balance (Figure 6). The immunomodulatory function of Treg cells is also closely related to the secretion of cytokines in peripheral blood plasma. IL-10 and TGF-β are secreted by Treg T cells, control inflammation, and regulate immunosuppression [34, 35]. In addition, TGF-β1 can induce the FoxP3 gene expression, participate in the accurate differentiation of Treg cells, and promote the survival of natural Treg cells [36]. Previous studies have demonstrated that TGF-β, which bind to cell membranes, increased the number of CD4^+ CD25^- Treg cells and also affected Treg function [37, 38]. SSLK intervention increased the serum levels of IL-10 and TGF-β in RHD patients (Figures 1(c) and 1(d)). A decrease in the secretion of IL-10 and TGF-β in the serum of RHD patients may affect the number of Treg cells and impair their functions. IL-10 polymorphism has been found to be associated with progression of RF/RHD, suggesting its important role in controlling CHD risk [39]. SSLK treatment reduced the levels of IL-1 and IL-6 and effectively controlled inflammation responses. There is significant deficiency of Tregs (CD4^+ CD25^+med-high)CD127(low) Foxp3(high)) in patients of chronic RHD [40] while increased percentage of Th17 cell-associated cytokines plays crucial roles in the progression of RHD [41].
The present work showed that SSLK treatment increased the percentages of CD4⁺CD25⁺FoxP3 Treg cells and reduced the percentages of CD4⁺IL-17 T cells in a dose-dependent way (p < 0.05). The percentage of CD4⁺CD25⁺FoxP3 Treg cells had positive relationship with CK-MB, cTnT, CRP, and TNF-α (Figure 4). The percentage of CD4⁺IL-17 T cells had positive relationship with CK-MB, cTnT, CRP, and TNF-α (Figure 5). CK-MB and cTnT are the important cardiac biomarkers associated with RHD risk [42]. CRP [43] and TNF-α [44] are related to the inflammation of CHD. Thus, SSLK ameliorated RHD by affecting CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T cells.

Notably, to reduce inflammation, low-dose aspirin (50 mg/daily) was orally administrated in both group [45]. Although aspirin has been reported to increase the numbers of Treg cells, its effects on the control group were not found when compared with before treatment [46]. On the other hand, in the present study, the normal percentages of Treg and Th17 cells were not found in CHD patients, which may be caused by the small size (40 subjects in each group). The effects of SSLK on the CHD patients with normal percentages of CD4⁺CD25⁺FoxP3 Treg and CD4⁺IL-17 T cells remain unclear. However, according to another report, the normal percentage of Treg cells should be existing even in severe gastrointestinal inflammation [47]. Much work needs to address these important issues in the future.

The cases of fatigue, chest pain, palpitation, and short breathing are the common complications of RHD. In the present study, the symptoms of fatigue and palpitation were all improved after SSLK intervention (Table 2, p < 0.05). Adverse reaction of SSLK was also analyzed, 2 patients had dizziness, weakness (1 case), and headache (1 case), and there were no liver, or kidney dysfunction, and/or other clinical abnormalities in the SSLK group. Notably, a SSLK treatment duration was 3 months. Traditional Chinese medicine is quite different with normal drug and cannot exert its function in human body immediately, and several months will be considered [48].

There are some limitations to the present work. The subsequent clinical characteristics were not investigated further after stopping taking SSLK. In addition, CD4⁺CD25⁺Treg cells was only detected in PBMCs from peripheral blood, and our results would be affected by the fact that Treg cells were a small fraction in RHD patients. An additional marker FoxP3 was used to distinguish between functional Treg cells and immature nonfunctional Treg cells. Therefore, further study should be performed to observe FOXP3 gene expression in the CD4⁺CD25⁺ Treg cells. The epigenetic regulation of CD4⁺CD25⁺Treg cells is closely related to human heart diseases. Therefore, it is very important to evaluate the epigenetic regulation of FoxP3 gene in RHD patients. The small sample size of this study should be further expanded to a larger population of RHD patients and follow-up period should be longer in order to gain the key advantages of SSLK. In Figure 1(d), the treatment seems to induce a separation for TGF-β between two different patient populations in the SG group (the median cuts sharply between two groups of red dots). The problem may be caused by small population size. To address these issues, further work is highly demanded in the future.

5. Conclusions

SSLK treatment improved MAP, HR, CVP, fatigue, palpitation, and shortness breath in the CHD patients. Meanwhile, SSLK intervention reduced the levels of blood lactate, CK-MB, cTnT, CRP, IL-1β, IL-6, TNF-α, and MDA and increased SOD level. SSLK treatment reduced the levels of IL-1β and IL-6 and increased the levels of IL-10 and TGF-β. SSLK had better anti-inflammatory effects. No increased risk of serious adverse reactions such as bleeding was found. SSLK treatment increased the percentage of CD4⁺CD25⁺FoxP3
Treg cells and reduced the percentage of CD4+IL-17 T cells. SSLK ameliorated RHD by affecting the percentage of CD4+CD25+FoxP3 Treg and CD4+IL17 T cells.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Tiechao Jiang and Qini Zhao equally contributed to the work.

**References**

[1] M. Yacoub, B. Mayosi, A. ElGuindy, A. Carpentier, and S. Yusuf, “Eliminating acute rheumatic fever and rheumatic heart disease,” *The Lancet*, vol. 390, no. 10091, pp. 212–213, 2017.

[2] Z. M. Makrezeni and L. Pepeta, “Clinical presentation and outcomes of patients with acute rheumatic fever and rheumatic heart disease seen at a tertiary hospital setting in Port Elizabeth, South Africa,” *Cardiovascular Journal of Africa*, vol. 28, no. 4, pp. 248–250, 2017.

[3] E. Teker, A. B. Akadam-Teker, O. Ozturk et al., “Association between the interferon gamma 874 T/A polymorphism and the severity of valvular damage in patients with rheumatic heart disease,” *Biochemical Genetics*, vol. 56, no. 3, pp. 225–234, 2018.

[4] T. Suzuki, M. Mawatari, T. lizuka et al., “An ineffective differential diagnosis of infective endocarditis and rheumatic heart disease after streptococcal skin and soft tissue infection,” *Internal Medicine*, vol. 56, no. 17, pp. 2361–2365, 2017.

[5] U. Abdullahi, S. Kana, M. Yakasai et al., “Update on rheumatic heart disease in Kano: data from the Aminu Kano Teaching Hospital echocardiography registry,” *Nigerian Journal of Basic and Applied Sciences*, vol. 14, no. 2, pp. 127–130, 2017.

[6] D. Engelman, R. L. Mataika, J. H. Kado et al., “Adherence to secondary antibiotic prophylaxis for patients with rheumatic heart disease diagnosed through screening in Fiji,” *Tropical Medicine & International Health*, vol. 21, no. 12, pp. 1583–1591, 2016.

[7] N. Zegeye, D. Asrat, Y. Woldeamanuel et al., “Throat culture positivity rate and antibiotic susceptibility pattern of beta-hemolytic streptococci in children for secondary prophylaxis for rheumatic heart disease,” *BMC Infectious Diseases*, vol. 16, no. 1, pp. 510–517, 2016.

[8] T. Iikebe, R. Okuno, M. Sasaki et al., “Molecular characterization and antibiotic resistance of Streptococcus dysgalactiae subspecies equisimilis isolated from patients with streptococcal toxic shock syndrome,” *Journal of Infection and Chemotherapy*, vol. 24, no. 2, pp. 117–122, 2018.

[9] U. Kamenske, N. Tesic, G. Sersa, and M. Cemazar, “Clinically usable interleukin 12 plasmid without an antibiotic resistance gene: Functionality and toxicity study in murine melanoma model,” *Cancers*, vol. 10, no. 3, article E60, 2018.

[10] L. Mizera, T. Geisler, K. Mörike, M. Gawaz, and M. Steeg, “Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists,” *BMJ Case Reports*, vol. 2018, no. 2, Article ID bcr-2016-215155, 2018.

[11] Y. Wu, J. Li, J. Wang et al., “Anti-atherogenic effects of centipede acidic protein in rats fed an atherogenic diet,” *Journal of Ethnopharmacology*, vol. 122, no. 3, pp. 509–516, 2009.

[12] Z. Zhao, J. Li, and Y. Jiang, “Influence of centipede acidic protein on cardiac function in rats with acute heart failure,” *Journal of Beijing University of Traditional Chinese Medicine*, vol. 31, no. 2, pp. 106–112, 2008.

[13] H. Zeng, S. Su, X. Xiang et al., “Comparative analysis of the major chemical constituents in Salvia miltiorrhiza roots, stems, leaves and flowers during different growth periods by UPLC-TQ-MS/MS and HPLC-ELSD methods,” *Molecules*, vol. 22, no. 5, article 771, 2017.

[14] A. H. Mohamed, E. Zaid, N. M. El-Beih, and A. Abd El-Aal, “Effects of an extract from the centipede Scopelomorpha moristans on intestine, uterus and heart contractions and on blood glucose and liver and muscle glycogen levels,” *Toxicol.*, vol. 18, no. 5-6, pp. 581–589, 1980.

[15] H. J. Park, B. Y. Chung, M.-K. Lee et al., “Centipede grass exerts anti-adipogenic activity through inhibition of C/EBPbeta, C/EBPalpha, and PPARgamma expression and the AKT signaling pathway in 3T3-L1 adipocytes,” *BMC Complementary and Alternative Medicine*, vol. 12, no. 230, pp. 1–9, 2012.

[16] D. Gorton, S. Sidker, N. L. Williams et al., “Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease,” *Autoimmunity*, vol. 49, no. 8, pp. 563–570, 2016.

[17] R. Chu, S. Y. Liu, A. C. Vlantis et al., “Inhibition of Foxp3 in cancer cells induces apoptosis of thyroid cancer cells,” *Molecular and Cellular Endocrinology*, vol. 399, no. 1, pp. 228–234, 2015.

[18] J. Y. Hong, M. Kim, I. S. Sol et al., “Chitotriosidase inhibits allergic asthmatic airways via regulation of TGF-β expression and Foxp3+ Treg cells,” *Allergy: European Journal of Allergy and Clinical Immunology*, vol. 73, no. 8, pp. 1686–1699, 2018.

[19] R. Torii, T. Yamashita, C. Furutani, H. Nakayama, and Y. Fugio, “CD4+CD25+regulatory T cells (Treg cells) migrate into hearts in experimental autoimmune myocarditis (EAM),” *Journal of Pharmacological Sciences*, vol. 121, no. 1, pp. 96–97, 2013.

[20] J. L. Hwang, S.-Y. Park, H. Ye et al., “FOXP3 mutations causing early-onset insulin-requiring diabetes but without other features of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome,” *Pediatric Diabetes*, vol. 19, no. 3, pp. 388–392, 2018.

[21] C. Griswold, A. R. Durica, L. G. Dennis, and A. F. Jewell, “Prenatal bowel findings in male siblings with a confirmed FOXP3 mutation,” *Journal of Ultrasound in Medicine*, vol. 37, no. 4, pp. 1033–1037, 2018.

[22] M. Cavalcanti-Neto, R. Prado, A. Piñeros et al., “Improvement of the resistance against early Mycobacterium tuberculosis-infection in the absence of PI3Kgamma enzyme is associated with increase of CD4+IL-17+ cells and neutrophils,” *Tuberculosis*, vol. 113, pp. 1–9, 2018.

[23] A. Barczyk, W. Pierzchala, G. Caramori et al., “Decreased group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease,” *BMC Infection Disease*, vol. 11, no. 1, pp. 1–9, 2011.

[24] M. Ozsarac, O. Karcigolu, C. Ayrik, F. Somuncu, and S. Gumrukcu, “Acute coronary ischemia following centipede envenomation: Case report and review of the literature,” *Wilderness & Environmental Medicine*, vol. 15, no. 2, pp. 109–112, 2004.
[25] H. D. Bas, K. Baser, E. Yavuz et al., “High Th17/Treg ratio in rheumatic heart disease,” *European Heart Journal*, vol. 34, pp. 697–698, 2013.

[26] C. J. Neely, R. Maile, M.-J. Wang, S. Vadlamudi, A. A. Meyer, and B. A. Cairns, “Th17 (IFNγ- IL17+) CD4+ T cells generated after burn injury may be a novel cellular mechanism for postburn immunosuppression,” *Journal of Trauma - Injury Infection and Critical Care*, vol. 70, no. 3, pp. 681–690, 2011.

[27] X. Yang, W. Wang, J. Xu et al., “Significant association of CD4+CD25+Foxp3+ regulatory T cells with clinical findings in patients with systemic lupus erythematosus,” *Annals of Translational Medicine*, vol. 7, no. 5, p. 93, 2019.

[28] A. Murata, T. Kasai, Y. Matsue et al., “Relationship between blood urea nitrogen-to-creatinine ratio at hospital admission and long-term mortality in patients with acute decompensated heart failure,” *Heart and Vessels*, vol. 33, no. 8, pp. 877–885, 2018.

[29] R. Bascom, K. Tao, S. Tollefson, and L. West, “Injected allogeneic CD4(+) CD25(+) Tregs regulate the neonatal immune system and prolong heart allograft survival,” *American Journal of Transplantation*, vol. 13, pp. 362–362, 2013.

[30] P. Kanellakis, T. N. Dinh, A. Agrotis, and A. Bobik, “CD4+ CD25+ Foxp3+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart,” *Journal of Hypertension*, vol. 29, no. 9, pp. 1820–1828, 2011.

[31] W. G. You, J. H. Lee, Y. Shin et al., “Antimicrobial peptides in the centipede Scolopendra subspinips mutilans,” *Functional & Integrative Genomics*, vol. 14, no. 2, pp. 275–283, 2014.

[32] Z.-C. Liu, R. Zhang, F. Zhao et al., “Venomic and transcriptomic analysis of centipede scolopendra subspinips dehaani,” *Journal of Proteome Research*, vol. 11, no. 5, pp. 6197–6212, 2012.

[33] Y. Wang, X. Li, M. Yang et al., “Centipede venom peptide SmstX-I with two intramolecular disulfide bonds shows analgesic activities in animal models,” *Journal of Peptide Science*, vol. 23, no. 5, pp. 384–391, 2017.

[34] Z. Yang, Y. Qi, N. Lai et al., “Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-beta1,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 1, 2018.

[35] K. Torres-Poveda, M. Bahena-Roman, C. Madrid-Gonzalez et al., “Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia,” *World Journal of Clinical Oncology*, vol. 5, no. 4, pp. 753–763, 2014.

[36] E. Elkord, S. Sharma, D. J. Burt, and R. E. Hawkins, “Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express helios, indicating they could be derived from natural but not induced Tregs,” *Clinical Immunology*, vol. 140, no. 3, pp. 218–222, 2011.

[37] L. Islas-Vazquez, H. Frado-Garcia, D. Aguilar-Cazares et al., “LAP TGF-beta subset of CD4+CD25+CD127- Treg cells is increased and overexpresses LAP TGF-beta in lung adenocarcinoma patients,” *BioMed Research International*, vol. 2015, Article ID 430943, II pages, 2015.

[38] Z. Y. Chen, Q. Xu, J. B. Ding, Y. Zhang, R. Du, and Y. Ding, “CD4+ CD25+Foxp3+ Treg and TGF-beta play important roles in pathogenesis of Uygur cervical carcinoma,” *European Journal of Gynaecological Oncology*, vol. 33, no. 5, pp. 502–507, 2012.

[39] N. Sharma and D. Toor, “Interleukin-10: Role in increasing susceptibility and pathogenesis of rheumatic fever/rheumatic heart disease,” *Cytokine*, vol. 90, pp. 169–176, 2017.

[40] S. Mukhopadhyay, S. Varma, H. N. Mohan Kumar et al., “Circulating level of regulatory T cells in rheumatic heart disease: an observational study,” *Indian Heart Journal*, vol. 68, no. 3, pp. 342–348, 2016.

[41] Y. Wen, Z. Zeng, C. Gui, L. Li, and W. Li, “Changes in the expression of Th17 cell-associated cytokines in the development of rheumatic heart disease,” *Cardiovascular Pathology*, vol. 24, no. 6, pp. 382–387, 2015.

[42] C. Wei, S. Zhang, J. Liu, R. Yuan, and M. Liu, “Relationship of cardiac biomarkers with white matter intensities in cardioembolic stroke due to atrial fibrillation and/or rheumatic heart disease,” *Medicine*, vol. 97, no. 33, p. e11892, 2018.

[43] A. Attar, P. Marzban, A. Moaref, and K. Aghasadeghi, “The association of plasma high-sensitivity C-reactive protein level with rheumatic heart disease: the possible role of inflammation,” *Indian Heart Journal*, vol. 70, no. 3, pp. 346–349, 2018.

[44] U. Gupta, S. S. Mir, N. Garg, S. K. Agarwal, P. Bandyopadhyay, and B. Mit, “Association study of inflammatory genes with rheumatic heart disease in North Indian population: A multi-analytical approach,” *Immunology Letters*, vol. 174, pp. 53–62, 2016.

[45] J. Chen, J. Zhao, J. Huang, S. Su, B. Qiang, and D. Gu, “717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study,” *Journal of Molecular Medicine (Berlin)*, vol. 83, no. 1, pp. 72–78, 2005.

[46] J. Zhu and B. Gao, “Simvastatin combined with aspirin increases the survival time of heart allograft by activating CD4+ CD25+ Tregs and enhancing vascular endothelial cell protection,” *Cardiovascular Pathology*, vol. 24, no. 3, pp. 173–178, 2015.

[47] E. Janssen, M. Tohme, S. Ullas, and R. Geha, “DOCK8 associates with STAT5 and promotes regulatory T cell function,” *Arthritis & Rheumatology*, vol. 68, 2016.

[48] M. Hong, C. Hong, H. Chen et al., “Effects of the Chinese herb formula Yufeining on stable chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial,” *Medicine*, vol. 97, no. 39, p. e12461, 2018.